<DOC>
	<DOCNO>NCT01166061</DOCNO>
	<brief_summary>Grass pollen allergen universally recognise major cause allergic disease human animal , include asthma , allergic rhinitis , conjunctivitis dermatitis . Worldwide , least 40 % allergic patient sensitized grass pollen allergens 50-90 % hayfever seasonal allergy sufferer allergic grass pollen . ToleroMune Grass novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment grass allergy . The purpose present study evaluate safety tolerability multiple ascending dos ToleroMune Grass subject allergic grass .</brief_summary>
	<brief_title>Safety Tolerability ToleroMune Grass Grass Allergic Subjects With Rhinoconjunctivitis</brief_title>
	<detailed_description>This study design randomise , double-blind , placebo-controlled study evaluate safety tolerability escalate multiple dos ToleroMune Grass subject document history allergic rhinoconjunctivitis exposure grass . The efficacy ToleroMune HDM also explore LPSR , EPSR , CPT level grass specific IgE . The study consist 3 study period . In Period 1 , Screening perform maximum 6 week randomisation . Period 2 ( Treatment Period ) consist 4 visit ( Visits 3A-3D ) four week apart . The first cohort receive low dose successive dose group increase dos ToleroMune Grass , provide first administration previous dose safe well tolerate . In Period 3 , 2 Post-treatment Challenge visit take place , first 2 week last administration Treatment Period second 17 week first administration . Follow-up conducted 3-10 day second PTC .</detailed_description>
	<criteria>Male female , age 1865 year Minimum 2 year history rhinoconjunctivitis exposure grass Positive skin prick test whole grass allergen LPSR whole grass allergen 810 hour intradermal injection great 35mm diameter response Positive CPT whole grass allergen score â‰¥4 Subjects history asthma Subjects FEV1 &lt; 80 % predicted Subjects rye grass specific IgE &gt; 100 kU/L Subjects acute phase skin response whole grass allergen mean wheal diameter &gt; 50 mm Subjects score &gt; 1 redness conjunctiva water itchiness eye administration CPT Treatment betablockers , alphaadrenoreceptor blocker , tranquilliser psychoactive drug History significant disease disorder ( e.g . cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Grass Allergy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>ToleroMune Grass</keyword>
</DOC>